Cargando…

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study

Triple Negative Breast Cancer (TNBC) is an aggressive neoplasia with median Overall Survival (OS) less than two years. Despite the availability of new drugs, the chance of survival of these patients did not increase. The combination of low doses of drugs in a metronomic schedule showed efficacy in c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerrito, Maria Grazia, De Giorgi, Marco, Pelizzoni, Davide, Bonomo, Sara Maria, Digiacomo, Nunzio, Scagliotti, Arianna, Bugarin, Cristina, Gaipa, Giuseppe, Grassilli, Emanuela, Lavitrano, Marialuisa, Giovannoni, Roberto, Bidoli, Paolo, Cazzaniga, Marina Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007943/ https://www.ncbi.nlm.nih.gov/pubmed/29937997 http://dx.doi.org/10.18632/oncotarget.25422

Ejemplares similares

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study
por: Cazzaniga, M. E., et al.
Publicado: (2014)

The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells
por: Romano, Gabriele, et al.
Publicado: (2016)

p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors
por: Grassilli, Emanuela, et al.
Publicado: (2021)

Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation
por: Scagliotti, Arianna, et al.
Publicado: (2022)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

GSK3A Is Redundant with GSK3B in Modulating Drug Resistance and Chemotherapy-Induced Necroptosis
por: Grassilli, Emanuela, et al.
Publicado: (2014)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
por: Cazzaniga, M. E., et al.
Publicado: (2016)

Simultaneous Overexpression of Functional Human HO-1, E5NT and ENTPD1 Protects Murine Fibroblasts against TNF-α-Induced Injury In Vitro
por: Cinti, Alessandro, et al.
Publicado: (2015)

Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients
por: Conconi, Donatella, et al.
Publicado: (2016)

Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma
por: Qin, Rong-Sheng, et al.
Publicado: (2018)

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study
por: Liu, Chien-Ting, et al.
Publicado: (2021)

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells
por: Krajnak, Slavomir, et al.
Publicado: (2023)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)

Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells
por: Biziota, Eirini, et al.
Publicado: (2016)

Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
por: Trevisan, B., et al.
Publicado: (2023)

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial
por: Guetz, Sylvia, et al.
Publicado: (2017)

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
por: Giordano, Federica, et al.
Publicado: (2019)

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer
por: Pujol, Jean-Louis, et al.
Publicado: (2019)

Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience
por: Rossi, David
Publicado: (2020)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
por: Gebbia, Vittorio, et al.
Publicado: (2020)

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022)

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
por: Sala, Luca, et al.
Publicado: (2019)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
por: Chi, Yajing, et al.
Publicado: (2022)

Víctor Cordero : compositor folklórico, poeta del pueblo/
por: Concepción, María
Publicado: (1971)

Metronomic 5-Fluorouracil Delivery Primes Skeletal Muscle for Myopathy but Does Not Cause Cachexia
por: Campelj, Dean G., et al.
Publicado: (2021)

Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
por: Villa, Federica, et al.
Publicado: (2023)

Victor Horta /
Publicado: (2003)

Victor Hugo
por: Billardière, Jacques
Publicado: (1993)

Víctor Erice /
por: Arocena, Carmen
Publicado: (1996)

Victor Pereira
por: Marwaha, Seema
Publicado: (2021)

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
por: Briasoulis, Evangelos, et al.
Publicado: (2013)

Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer
por: D'Ascanio, Michela, et al.
Publicado: (2018)

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
por: Bonneterre, J, et al.
Publicado: (2002)

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia
por: Sarno, Jolanda, et al.
Publicado: (2018)

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
por: Camerini, Andrea, et al.
Publicado: (2015)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pod8heff2u5746rv336ebru0e6